. 2022 Mar 30;14(7):1755. doi: 10.3390/cancers14071755

Table 3.

Randomized Controlled Trials (RCTs) Evaluating Esophageal and Gastroesophageal Junction (GEJ) Adenocarcinoma (AC).

Author	Year	Name	Type	Timing	n	C	R (Gy)	OS M	Other	Metric	p-Value
Neoadjuvant Chemotherapy vs. Surgery Alone
Ychou et al. [35]	2011	-	Phase III	Pre + Post	113	F + Ci	-	-	0.69	HR OS	p = 0.02
Ychou et al. [35]	2011	-	Phase III	-	111	-	-	-	0.69	HR OS	p = 0.02
Neoadjuvant Chemotherapy
Lorenzen et al. [36]	2013	FLOT 65+	Phase II	Pre + Post	21	F + L + O + T2	-	-	2.02	HR PFS	p = 0.09
Lorenzen et al. [36]	2013	FLOT 65+	Phase II	Pre + Post	22	F + L + O	-	-	2.02	HR PFS	p = 0.09
Cunningham et al. [37]	2017	MRC ST03	Phase II/III	Pre + Post	530	Ce + Ci + Ep + Bb	-	-	1.08	HR OS	p = 0.36
Cunningham et al. [37]	2017	MRC ST03	Phase II/III	Pre + Post	533	Ce + Ci + Ep	-	-	1.08	HR OS	p = 0.36
Alderson et al. [38]	2017	MRC OE05	Phase III	Pre	451	F + Ci	-	-	0.90	HR OS	p = 0.19
Alderson et al. [38]	2017	MRC OE05	Phase III	Pre	446	Ce + Ci + Ep	-	-	0.90	HR OS	p = 0.19
Al-Batran et al. [39]	2019	FLOT4	Phase II/III	Pre + Post	360	F/Ce + Ci + Ep	-	35	0.77	HR OS	NS, p = 0.012
Al-Batran et al. [39]	2019	FLOT4	Phase II/III	Pre + Post	356	F + L + O + T2	-	50	0.77	HR OS	NS, p = 0.012
Zhang et al. [40]	2021	RESOLVE	Phase III	Post	345	Ce + O	-	-	0.86	HR DFS	p = 0.170
				Post	340	S1 + O	-	-	0.86	HR DFS	p = 0.170
				Pre + Post	337	S1 + O	-	-	0.77	HR DFS	p = 0.027
Neoadjuvant Chemoradiation vs. Surgery Alone
Zhao et al. [41]	2015	-	Phase II	Pre	36	Ce + O	45	-	100%	R0	p = 0.045
Zhao et al. [41]	2015	-	Phase II	-	40	-	-	-	80%	R0	p = 0.045
Tian et al. [42]	2021	-	Phase II	Pre	63	Ce + O	45	-	63%	3 Y OS	p = 0.019
Tian et al. [42]	2021	-	Phase II	-	69	-	-	-	52%	3 Y OS	p = 0.019
Neoadjuvant Chemoradiation
Stahl et al. [43]	2009	-	Phase III	Pre	45	F + L + Ci × 2	30	33.1	-	-	NS
Stahl et al. [43]	2009	-	Phase III	Pre	49	F + L + Ci	-	21.1	-	-	NS
Burmeister et al. [44]	2011	-	Phase II	Pre	39	F + Ci	35	32	-	-	p = 0.83
Burmeister et al. [44]	2011	-	Phase II	Pre	36	F + Ci	-	29	-	-	p = 0.83
Ajani et al. [45]	2013	-	Phase II	Pre	63	F + O x 2	50.4	43.7	-	-	p = 0.69
Ajani et al. [45]	2013	-	Phase II	Pre	63	F + O	50.4	45.6	-	-	p = 0.69
Stahl et al. [46]	2017	POET	Phase III	Pre	33	F + L + Ci & Ci + Et	30	30.8	0.65	HR OS	NS, p = 0.055
Stahl et al. [46]	2017	POET	Phase III	Pre	32	F + L + Ci	-	21.1	0.65	HR OS	NS, p = 0.055
Barbour et al. [47]	2020	AGITG DOCTOR	Phase II	Pre	35	F + Ci + T2	45	35	-	-	NS
Barbour et al. [47]	2020	AGITG DOCTOR	Phase II	Pre	31	F + Ci + T2	-	30	-	-	NS
Mukherjee et al. [48]	2021	NeoSCOPE	Phase II	Pre	42	Ce + O	45	-	0.48	HR OS	p = 0.035
Mukherjee et al. [48]	2021	NeoSCOPE	Phase II	Pre	43	Co + T	45	-	0.48	HR OS	p = 0.035

n = Sample Size; C = Chemotherapy; R (Gy) = Radiation Gray; OS M = Overall Survival in Months; RCT = Randomized Controlled Trial; F = 5-FU or 5-Fluorouracil; L = Leucovorin; Ci = Cisplatin; Co = Carboplatin; T = Paclitaxel; T2 = Docetaxel; B = Bleomycin; Et = Etoposide; Vb = Vinblastine; Vd = Vindesine; O = Oxaliplatin; Ep = Epirubicin; Ce = Capecitabine; Bb = Bevacizumab; FO = Oral Fluorouracil; Int = Intratumoral Injection; 1 Y OS = 1 Year Overall Survival; 2 Y OS = 2 Year Overall Survival; 3 Y OS = 3 Year Overall Survival; 5 Y OS = 5 Year Overall Survival; HR DFS = Hazard Ratio Disease Free Survival; HR OS = Hazard Ratio Overall Survival; HR PFS = Hazard Ratio Progression Free Survival; R0 = Microscopic Margin Free Resection; NS = No Significance/Value Not Reported.